{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=91",
    "query": {
      "condition": "Safety Study",
      "page": 91
    },
    "page_size": 10
  },
  "pagination": {
    "page": 91,
    "page_size": 10,
    "total_count": 33600,
    "total_pages": 3360,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=92&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=90&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T21:21:22.018Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04839523",
      "title": "Performance and Safety of Exufiber Ag+ and Exufiber on Partial Thickness Burns",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Partial-thickness Burn"
      ],
      "interventions": [
        {
          "name": "Exufiber",
          "type": "DEVICE"
        },
        {
          "name": "Exufiber Ag+",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Molnlycke Health Care AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Weeks",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Weeks and older"
      },
      "enrollment_count": 44,
      "start_date": "2021-03-10",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-11-12",
      "last_synced_at": "2026-11-21T21:21:22.018Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04839523"
    },
    {
      "nct_id": "NCT04706923",
      "title": "A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenovirus Infections",
        "Cytomegalovirus Infection"
      ],
      "interventions": [
        {
          "name": "BCV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SymBio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Months and older"
      },
      "enrollment_count": 53,
      "start_date": "2021-08-16",
      "completion_date": "2025-05-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-11-21T21:21:22.018Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • San Francisco, California • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04706923"
    },
    {
      "nct_id": "NCT05822752",
      "title": "Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Budigalimab",
          "type": "DRUG"
        },
        {
          "name": "Livmoniplimab",
          "type": "DRUG"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2023-09-21",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-11-21T21:21:22.018Z",
      "location_count": 20,
      "location_summary": "Prescott Valley, Arizona • Springdale, Arkansas • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Prescott Valley",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05822752"
    },
    {
      "nct_id": "NCT01496352",
      "title": "DFA-02 in Patients Undergoing Colorectal Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Surgical Site Infection"
      ],
      "interventions": [
        {
          "name": "DFA-02",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dr. Reddy's Laboratories Limited, India",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2012-02",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2014-09-01",
      "last_synced_at": "2026-11-21T21:21:22.018Z",
      "location_count": 5,
      "location_summary": "Florence, Alabama • Tampa, Florida • Columbus, Ohio + 2 more",
      "locations": [
        {
          "city": "Florence",
          "state": "Alabama"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Bellaire",
          "state": "Texas"
        },
        {
          "city": "Temple",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01496352"
    },
    {
      "nct_id": "NCT06468826",
      "title": "A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "End-Stage Renal Disease (ESRD)"
      ],
      "interventions": [
        {
          "name": "Avacopan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 13,
      "start_date": "2024-06-18",
      "completion_date": "2024-10-05",
      "has_results": true,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-11-21T21:21:22.018Z",
      "location_count": 2,
      "location_summary": "Miami Lakes, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06468826"
    },
    {
      "nct_id": "NCT00941278",
      "title": "An Efficacy and Safety Study of PH-10 Aqueous Hydrogel for the Treatment of Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "PH-10 (0.001% Rose Bengal)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Provectus Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2009-07",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2010-07-07",
      "last_synced_at": "2026-11-21T21:21:22.018Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • New York, New York",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00941278"
    },
    {
      "nct_id": "NCT03566043",
      "title": "CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Mucopolysaccharidosis Type II (MPS II)"
      ],
      "interventions": [
        {
          "name": "RGX-121",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "REGENXBIO Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "5 Years",
        "sex": "MALE",
        "summary": "4 Months to 5 Years · Male only"
      },
      "enrollment_count": 48,
      "start_date": "2018-09-27",
      "completion_date": "2025-08",
      "has_results": false,
      "last_update_posted_date": "2025-01-28",
      "last_synced_at": "2026-11-21T21:21:22.018Z",
      "location_count": 4,
      "location_summary": "Oakland, California • New Brunswick, New Jersey • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03566043"
    },
    {
      "nct_id": "NCT01770743",
      "title": "A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anthrax"
      ],
      "interventions": [
        {
          "name": "AV7909",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BioThrax",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 168,
      "start_date": "2013-01",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-11-21T21:21:22.018Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Mt. Pleasant, South Carolina • New Braunfels, Texas + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        },
        {
          "city": "New Braunfels",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01770743"
    },
    {
      "nct_id": "NCT00015808",
      "title": "Safety Study of Idebenone to Treat Friedreich's Ataxia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Friedreich Ataxia"
      ],
      "interventions": [
        {
          "name": "Idebenone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 100,
      "start_date": "2001-05",
      "completion_date": "2006-04",
      "has_results": false,
      "last_update_posted_date": "2006-07-12",
      "last_synced_at": "2026-11-21T21:21:22.018Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00015808"
    },
    {
      "nct_id": "NCT01552408",
      "title": "Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "0.3 mg ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Targeted Pan Retinal Photocoagulation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "David M. Brown, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2012-03",
      "completion_date": "2017-05-18",
      "has_results": true,
      "last_update_posted_date": "2018-10-05",
      "last_synced_at": "2026-11-21T21:21:22.018Z",
      "location_count": 3,
      "location_summary": "Houston, Texas • Katy, Texas • The Woodlands, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Katy",
          "state": "Texas"
        },
        {
          "city": "The Woodlands",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01552408"
    }
  ]
}